Empty Capsule Plant Project Report: Industry Trends, Plant Setup, Machinery, Raw Materials, Investment Opportunities, Cost and Revenue

Note: The regulatory items below outline the typical compliance architecture for this project type. Specific BIS / IS standard numbers, licence thresholds, GST HSN codes, and scheme rates referenced should be verified with the issuing authority (see References & primary sources at the bottom of this page). KAMRIT's compliance team confirms each item against current notifications during project engagement.

Empty capsule plant sits under India's strictest regulatory regime (CDSCO at the centre, state Drug Controllers, plus WHO-GMP and Schedule M). For ₹4.5 crore - ₹80 crore CapEx this DPR captures:

• Plant Master File (PMF) and Site Master File (SMF) for export dossier
• NABL accreditation for QC lab, BSL-2/BSL-3 containment certification where applicable
• Bio-medical waste authorisation under BMW Rules 2016
• PLI Bulk Drugs (₹15,000 cr) or PLI Medical Devices (₹3,420 cr) participation
• NABH / NABL accreditation if the project includes a clinical or diagnostic arm
• Manufacturing licence under the Drugs and Cosmetics Act 1940 (Form 25/28/28A by category)

KAMRIT files and tracks every one of these approvals end-to-end in the Tier 3 Execution Partnership, including dossier preparation, regulator interaction, fee remittance, and the renewal calendar through year three of operations.

<p>The Indian empty capsule market is valued at approximately USD 1.699.5 million to USD 1.813.03 million in 2025, with projections to reach USD 3.462 million by 2035 at a CAGR of 6.68% per Market Research Future (2026). Broader global market intelligence varies by source: Grand View Research estimates the market at USD 4.90 billion by 2030, Fortune Data Vista forecasts USD 6.20 billion by 2033, and Spherical Insights projects USD 7.53 billion by 2033. The global market size in 2026 is estimated between USD 3.7 billion and USD 3.95 billion (Mordor Intelligence, 2026), with long-term projections reaching USD 4.9 billion to USD 7.4 billion by 2030-2036 at CAGRs ranging from 3.8% to 8.1%.</p><p>Material segment analysis reveals that gelatin capsules account for 60.2% to 75% of market demand in India as of 2025, with the gelatin segment globally valued at a 65.56% to 73.4% share in 2025.

Plant-based vegetarian alternatives, predominantly HPMC capsules, represent the fastest-growing sub-segment, with a projected non-gelatin growth rate of 10.25% CAGR through 2031. Gelatin production is forecast to reach 60.2% of total output by 2026 globally. Regional demand clusters in India are concentrated in the Baddi region of Himachal Pradesh, Sikkim, Telangana, and Maharashtra.

The sector's gross profit margins range from 40% to 50%, with net profit margins between 20% and 28%. Standard manufacturing facility annual capacities span 500 million to 2 billion capsules, while modern automated lines achieve output exceeding 250,000 to 300,000 capsules per hour.</p><p>Demand is driven by the expanding global geriatric population, projected to reach 1.6 billion individuals aged 65 and older by 2050. Rising prevalence of chronic diseases and polypharmacy, with over 40% of adults aged 65 and older taking five or more medications, further fuels capsule demand.

The softgel capsules segment alone in India is projected to achieve USD 685.6 million by 2030, growing at a 7.8% CAGR from 2023 to 2030. Consumer preference for preventive healthcare, wellness, and dietary supplementation underpins sustained long-term demand, with 60.2% of US adults aged 20 and older reported to be consuming dietary supplements.</p>

Project-specific demand drivers

• PLI Bulk Drug and Medical Devices
• US generics export opportunity
• Health insurance penetration rising
• Chronic disease burden growth
• Hospital capex expansion in Tier-2/3

<p>The manufacturing technology for empty capsules involves a highly specialized process combining precision tooling, controlled environmental conditioning, and automated quality inspection. Hard gelatin capsules are manufactured using a dip-pin method, where stainless steel molds (pins) are dipped into a gelatin solution base, followed by controlled drying, stripping, and finishing operations. Modern automated encapsulation and empty capsule manufacturing lines achieve output levels exceeding 250,000 to 300,000 capsules per hour.

Automation upgrades have significantly reduced manufacturing defect rates and improved operational consistency.</p><p>Standard hard gelatin capsule manufacturing line capital expenditure ranges from INR 10 crore to INR 14 crore per unit, with production capacities between 1 billion and 1.5 billion capsules per year and gross margins of 8% to 12%. HPMC (vegetarian) capsule plants require higher investment at INR 15 crore to INR 20 crore per unit but command superior gross margins of 18% to 24%. Specialty product lines, including colored and printed capsules, necessitate additional investment of INR 2 crore to INR 4 crore.

Manufacturing specifications require TSE/BSE-free raw material sourcing, moisture content targets between 13% and 16%, and standardized capsule sizes ranging from #000 (largest) to #5 (smallest). The organized sector's investment in advanced automated dip-pin and drying tunnel systems creates significant barriers to entry for new competitors.</p><p>Sustainability considerations are increasingly shaping manufacturing technology choices. Lonza / Capsugel has committed to a reduction goal of greater than 40% in Scope 1 and Scope 2 emissions by the end of 2030, with a net-zero greenhouse gas emissions target by 2050 or earlier.

Scope 1 and Scope 2 operational footprints account for 30% to 50% of a capsule's total lifecycle emissions, making energy-efficient drying and humidity control systems a strategic priority. Raw material costs dominate the operating expense structure: gelatin or HPMC accounts for 60% to 70% of total operating expenses, while utilities for temperature and humidity control and drying represent 20% to 25% of OpEx.</p>

For a empty capsule plant project at ₹4.5 crore - ₹80 crore CapEx with a 3.8 - 6.4-year payback, the bank-loan-ready Means of Finance KAMRIT recommends is 30-40% promoter equity and 60-70% debt. The primary lender pool for this scale is SBI MSME, Bank of Baroda, HDFC Bank, ICICI Bank, Axis Bank term loans plus working capital facilities. The applicable overlay schemes that materially compress effective cost-of-capital are CGTMSE up to ₹5 cr, PLI sector overlay where eligible, state capital subsidy. The Tier 2 Bankable DPR includes the full vendor-quote-backed CapEx schedule, OpEx model, 5-year revenue projection split by SKU and channel, working-capital cycle, ROI/NPV/IRR, break-even, and sensitivity in three scenarios (base / bull / bear). The model is structured for direct submission to a commercial bank or NBFC credit appraisal team.

<p>Raw material cost volatility represents the most significant operational risk for empty capsule manufacturers. Gelatin and HPMC together account for 60% to 70% of total operating expenses, making the sector highly exposed to bovine and porcine raw material price fluctuations, supply chain disruptions, and agricultural yield variability. Geographic concentration of gelatin sourcing and potential disease outbreaks affecting livestock herds can create acute supply constraints.

Utilities costs for temperature and humidity control and drying operations add another 20% to 25% to the operating expense base, creating sensitivity to energy price movements.</p><p>Antidumping duties pose a direct trade risk. Investigations and duties on gelatin imports or capsule exports can alter competitive dynamics and margin structures. The sector's exposure to international trade regulations, including requirements for TSE/BSE-free raw material certification and compliance with IP, BP, USP, and EP pharmacopoeial standards, adds ongoing compliance costs and operational complexity.

Regulatory requirements under the Drugs and Cosmetics Act and Rules, managed by the CDSCO, mandate manufacturing licenses (Form 25 or Form 28), and non-compliance can result in production suspension or market withdrawal.</p><p>Environmental and sustainability obligations are increasingly material. Scope 1 and Scope 2 operational emissions account for 30% to 50% of a capsule's total lifecycle footprint. Industry leaders such as Lonza / Capsugel have committed to greater than 40% emissions reduction targets by 2030 and net-zero by 2050.

Compliance with these targets requires capital investment in energy-efficient drying systems, renewable energy integration, and process optimization. BIS quality standards, while not always mandatory, are becoming de facto requirements for market access, particularly for export customers. The competitive intensity from established players like ACG Worldwide, with its 100 billion-plus annual capacity and global footprint, creates pricing pressure that can compress margins for new entrants and smaller-scale operators.</p>